company logo

Senior Director, Global Talent Acquisition at 10X Genomics in Pleasanton, CA



$200K — $250K *


HR Recruitment & Placement


11 - 15 years

Job Description

See More

Valid through: 11/28/2020

About 10X Genomics

10x Genomics is an American biotechnology company that designs and manufactures gene sequencing technology used in scientific research. It was founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness., 10x Genomics was founded in 2012 by Serge Saxonov, Ben Hindson and Kevin Ness to create advanced testing equipment for use in cellular biology. Prior to starting the company, Saxonov was the founding architect, and director of research and development at 23andMe. Ness left 10x Genomics in December 2016 and in 2018, Justin McAnear, Tesla's former finance chief joined the company as CFO., In August 2018 the company announced its first acquisition, Epinomics, a biotechnology company focused on the development of new techniques for epigenetics research. Four months later, 10x Genomics acquired Spatial Transcriptomics, a biotechnology company working in the field of spatial genomics. In November 2018, 10x Genomics announced expansion plans including opening a manufacturing facility in Pleasanton, California in early 2019., 10x Genomics announced its initial public offering on September 12, 2019, raising $390M. The company had revenues of $3.32 million in 2015, $27.48 million in 2016, $71.18 million in 2017 and $145 million in 2018., Saxonov, Hindson, and Ness worked together at Quantalife prior to its acquisition by Bio-Rad in 2011 and left in 2012 to launch 10x Genomics. In 2014 an arbitration dispute was brought against the three cofounders by Bio-Rad, claiming they had breached obligations they allegedly owed to Bio-Rad after it acquired Quantalife. In 2015 an arbitrator determined that the founders of 10x Genomics had not breached their obligation to Bio-Rad when they left the company and denied its claims., In November 2018, a Delaware jury found that 10x Genomics infringed on several University of Chicago patents which were exclusively licensed to Bio-Rad. 10x Genomics were ordered to pay $24 million in damages to Bio-Rad and a 15 % royalty on sales. 10x Genomics appealed the verdict but the decision was upheld in August 2020.
stats icon
Total Jobs:
stats icon
Average Pay:
stats icon
Total value of jobs:
Learn More About 10X Genomics view all icon
* Ladders Estimates